Cytochrome P450 enzymes in vascular homeostasis

Circulation Research

Volumn 89, Issue 9, 2001, Pages 753-762

  Fleming, Ingrid ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

20 hydroxyeicosatetraenoic acid; Endothelial dysfunction; Endothelium derived hyperpolarizing factor; Epoxyeicosatrienoic acids; Free radicals

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ARACHIDONIC ACID; CYTOCHROME P450; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; EPOXYICOSATRIENOIC ACID; FREE RADICAL; HYDROXYICOSATETRAENOIC ACID; ICOSANOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE; PROSTACYCLIN; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; VASCULAR CELL ADHESION MOLECULE 1; 20 HYDROXY 5,8,11,14 EICOSATETRAENOIC ACID; 20-HYDROXY-5,8,11,14-EICOSATETRAENOIC ACID; ALKANE 1 MONOOXYGENASE; BIOLOGICAL FACTOR; DIHOMO GAMMA LINOLENIC ACID; DRUG DERIVATIVE; ENDOTHELIUM DEPENDENT HYPERPOLARIZATION FACTOR; ENDOTHELIUM-DEPENDENT HYPERPOLARIZATION FACTOR; EPOXIDE; ISOENZYME; MIXED FUNCTION OXIDASE;

ANGIOGENESIS; ARTERY TONE; ATHEROSCLEROSIS; BLOOD VESSEL; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; HOMEOSTASIS; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASODILATATION; ADRENERGIC SYSTEM; ANIMAL; CARDIOVASCULAR SYSTEM; CYTOLOGY; DRUG EFFECT; METABOLISM; PHYSIOLOGY;

8,11,14-EICOSATRIENOIC ACID; ALKANE 1-MONOOXYGENASE; ANIMALS; ARACHIDONIC ACID; BIOLOGICAL FACTORS; CARDIOVASCULAR SYSTEM; CYTOCHROME P-450 ENZYME SYSTEM; ENDOTHELIUM, VASCULAR; EPOXY COMPOUNDS; FREE RADICALS; HOMEOSTASIS; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; ISOENZYMES; MIXED FUNCTION OXYGENASES; MUSCLE, SMOOTH, VASCULAR; VASOMOTOR SYSTEM;

EID: 0035955607     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/hh2101.099268     Document Type: Review

References (139)

1. Capdevila J, Chacos N, Werringloer J, Prough RA, Estabrook RW. Liver microsomal cytochrome P-450 and the oxidative metabolism of arachidonic acid. Proc Natl Acad Sci U S A. 1981;78:5362-5366.
2. +)ATPase. Nature. 1985;314:620-622.
3. Ca channels. Am J Physiol Heart Circ Physiol. 2001;280: H2430-H2440.
4. Oyekan AO, McAward K, Conetta J, Rosenfeld L, McGiff JC. Endothelin-1 and CYP450 arachidonate metabolites interact to promote tissue injury in DOCA-salt hypertension. Am J Physiol. 1999;276: R766-R775.
5. Scarborough PE, Ma J, Qu W, Zeldin DC. P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in extrahepatic tissues. Drug Metab Rev. 1999;31:205-234.
6. Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem. 1996; 271:3460-3468.
7. Lin JHC, Kobari Y, Zhu Y, Stemerman MB, Pritchard KA Jr. Human umbilical vein endothelial cells express P450 2C8 mRNA: cloning of endothelial P450 epoxygenase. Endothelium. 1996;4:219-229.
8. Guengerich FP. Human cytochrome P450 enzymes. In: Ortiz de Montellano PR, ed. Cytochrome P-450: Structure, Mechanism, and Biochemistry. New York, NY: Plenum Press; 1995:473-535.
9. Nguyen X, Wang MH, Reddy KM, Falck JR, Schwartzman ML. Kinetic profile of the rat CYP4A isoforms: arachidonic acid metabolism and isoform-specific inhibitors. Am J Physiol. 1999;276:R1691-R1700.
10. Coon MJ, Ding X, Pernecky SJ, Vaz ADN. Cytochrome P450: progress and predictions. FASEB J. 1992;6:669-673.
11. McGiff JC, Quilley J. 20-HETE and the kidney: resolution of old problems and new beginnings. Am J Physiol. 1999;277:R607-R623.
12. Wu S, Chen W, Murphy E, Gabel S, Tomer KB, Foley J, Steenbergen C, Falck JR, Moomaw CR, Zeldin DC. Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem. 1997;272:12551-12559.
13. VanRollins M, Kaduce TL, Fang X, Knapp HR, Spector AA. Arachidonic acid diols produced by cytochrome P-450 monooxygenases are incorporated into phospholipids of vascular endothelial cells. J Biol Chem. 1996;271:14001-14009.
14. Balazy M. Metabolism of 5,6-epoxyeicosatrienoic acid by the human platelet: formation of novel thromboxane analogs. J Biol Chem. 1991; 266:23561-23567.
15. Zhu Y, Schieber EB, McGiff JC, Balazy M. Identification of arachidonate P-450 metabolites in human platelet phospholipids. Hypertension. 1995;25:854-859.
16. Capdevila JH, Kishore V, Dishman E, Blair IA, Falck JR. A novel pool of rat liver inositol and ethanolamine phospholipids contains epoxyeicosatrienoic acids (EETs). Biochem Biophys Res Commun. 1987;146: 638-644.
17. Karara A, Dishman E, Falck JR, Capdevila JH. Endogenous epoxyeicosatrienoyl-phospholipids: a novel class of cellular glycerolipids containing epoxidized arachidonate moieties. J Biol Chem. 1991;266: 7561-7569.
18. Weintraub NL, Fang X, Kaduce TL, VanRollins M, Chatterjee P, Spector AA. Potentiation of endothelium-dependent relaxation by epoxyeicosatrienoic acids. Circ Res. 1997;81:258-267.
19. Shivachar AC, Willoughby KA, Ellis EF. Effect of protein kinase C modulators on 14,15-epoxyeicosatrienoic acid incorporation into astroglial phospholipids. J Neurochem. 1995;65:338-346.
20. Karara A, Wei S, Spady D, Swift L, Capdevila JH, Falck JR. Arachidonic acid epoxygenase: structural characterization and quantification of epoxyeicosatrienoates in plasma. Biochem Biophys Res Commun. 1992; 182:1320-1325.
21. Quilley J, McGiff JC. Is EDHF an epoxyeicosatrienoic acid? Trends Pharmacol Sci. 2000;21:121-124.
22. Hecker M, Bara AT, Bauersachs J, Busse R. Characterization of endothelium-derived hyperpolarizing factor as a cytochrome P450-derived arachidonic acid metabolite in mammals. J Physiol. 1994;481:407-414.
23. + channels. Circ Res. 1998;83:501-507.
24. + channels. Circulation. 2001;103: 1992-1998.
25. Bauersachs J, Hecker M, Busse R. Display of the characteristics of endothelium-derived hyperpolarizing factor by a cytochrome P450-derived arachidonic acid metabolite in the coronary microcirculation. Br J Pharmacol. 1994;113:1548-1553.
26. Fulton D, Mahboubi K, McGiff JC, Quilley J. Cytochrome P450-dependent effects of bradykinin in the rat heart. Br J Pharmacol. 1995; 114:99-102.
27. Popp R, Bauersachs J, Hecker M, Fleming I, Busse R. A transferable, β-naphthoflavone-inducible, hyperpolarizing factor is synthesised by native and cultured porcine coronary endothelial cells. J Physiol. 1996; 497:3:699-709.
28. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res. 1996;78:415-423.
29. Arima S, Endo Y, Yaoita H, Omata K, Ogawa S, Tsunoda K, Abe M, Takeuchi K, Abe K, Ito S. Possible role of P-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole. J Clin Invest. 1997; 100:2816-2823.
30. Fulton D, McGiff JC, Quilley J. Pharmacological evaluation of an epoxide as the putative hyperpolarizing factor mediating the nitric oxide-independent vasodilator effect of bradykinin in the rat heart. J Pharmacol Exp Ther. 1998;287:497-503.
31. + channels. Circulation. 1999;99: 3132-3138.
32. Nishikawa Y, Stepp DW, Chilian WM. In vivo location and mechanism of EDHF-mediated vasodilation in canine coronary microcirculation. Am J Physiol. 1999;277:H1252-H1259.
33. + channel in vascular smooth muscles by cytochrome P450 metabolites of arachidonic acids. Eur J Pharmacol. 1993;230:215-221.
34. Pratt PF, Li P, Hillard CJ, Kurian J, Campbell WB. Endothelium-independent, ouabain-sensitive relaxation of bovine coronary arteries by EETs. Am J Physiol Heart Circ Physiol. 2001;280:H1113-H1121.
35. 2+ influx. Biochem J. 1991;274:193-197.
36. + channels by cytochrome P-450 inhibitors. J Biol Chem. 1992;267:11789-11793.
37. Wang MH, Brand-Schieber E, Zand BA, Nguyen X, Falck JR, Balu N, Schwartzman ML. Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors. J Pharmacol Exp Ther. 1998;284:966-973.
38. Imig JD, Falck JR, Wei S, Capdevila JH. Epoxygenase metabolites contribute to nitric oxide-independent afferent arteriolar vasodilation in response to bradykinin. J Vasc Res. 2001;38:247-255.
39. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, Busse R. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature. 1999;401:493-497.
40. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 1999;285:1276-1279.
41. Fisslthaler B, Hinsch N, Chataigneau T, Popp R, Kiss L, Busse R, Fleming I. Nifedipine increases cytochrome P4502C expression and EDHF-mediated responses in coronary arteries. Hypertension. 2000;36: 270-275.
42. de Morais SMF, Schweikl H, Blaisdell J, Goldstein JA. Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18. Biochem Biophys Res Commun. 1993;194:194-201.
43. Mancy A, Dijols S, Poli S, Guengerich P, Mansuy D. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9. Biochemistry. 1996;35:16205-16212.
44. Sai Y, Dai R, Yang TJ, Krausz KW, Gonzalez FJ, Gelboin HV, Shou M. Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450. Xenobiotica. 2000;30:327-343.
45. Fleming I, Michaelis UR, Bredenkotter D, Fisslthaler B, Dehghani F, Brandes RP, Busse R. Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res. 2001;88:44-51.
46. 2+ changes and dilation in isolated resistance arteries. FASEB J. 2000;14:255-260.
47. Bauersachs J, Popp R, Hecker M, Sauer E, Fleming I, Busse R. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation. 1996;94:3341-3347.
48. Imig JD, Falck JR, Inscho EW. Contribution of cytochrome P450 epoxygenase and hydroxylase pathways to afferent arteriolar autoregulatory responsiveness. Br J Pharmacol. 1999;127:1399-1405.
49. Maier KG, Roman RJ. Cytochrome P450 metabolites of arachidonic acid in the control of renal function. Curr Opin Nephrol Hypertens. 2001;10:81-87.
50. Henrich WL, Falck JR, Campbell WB. Inhibition of renin release by 14,15-epoxyeicosatrienoic acid in renal cortical slices. Am J Physiol. 1990;258:E269-E274.
51. Alkayed NJ, Birks EK, Narayanan J, Petrie KA, Kohler-Cabot AE, Harder DR. Role of P-450 arachidonic acid epoxygenase in the response of cerebral blood flow to glutamate in rats. Stroke. 1997;28:1066-1072.
52. Harder DR, Roman RJ, Gebremedhin D. Molecular mechanisms controlling nutritive blood flow: role of cytochrome P450 enzymes. Acta Physiol Scand. 2000;168:543-549.
53. Jacobs ER, Zeldin DC. The lung HETEs (and EETs) up. Am J Physiol Heart Circ Physiol. 2001;280:H1-H10.
54. Drugge ED, Carroll MA, McGiff JC. Cells in culture from rabbit medullary thick ascending limb of Henle's loop. Am J Physiol. 1989; 256:C1070-C1081.
55. Oyekan AO, McGiff JC. Functional response of the rat kidney to inhibition of nitric oxide synthesis: role of cytochrome P450-derived arachidonate metabolites. Br J Pharmacol. 1998;125:1065-1073.
56. Oyekan AO, McAward K, McGiff JC. Renal functional effects of endothelins: dependency on cytochrome P450- derived arachidonate metabolites. Biol Res. 1998;31:209-215.
57. Croft KD, McGiff JC, Sanchez-Mendoza A, Carroll MA. Angiotensin II releases 20-HETE from rat renal microvessels. Am J Physiol Renal Physiol. 2000;279:F544-F551.
58. Imig JD. Eicosanoid regulation of the renal vasculature. Am J Physiol Renal Physiol. 2000;279:F965-F981.
59. Harder DR, Lange AR, Gebremedhin D, Birks EK, Roman RJ. Cytochrome P450 metabolites of arachidonic acid as intracellular signaling molecules in vascular tissue. J Vasc Res. 1997;34:237-243.
60. +-ATPase. J Clin Invest. 1997;9:1224-1230.
61. +-ATPase are age dependent. Am J Physiol Renal Physiol. 2000;278:F823-F829.
62. Bayliss WM. On the local regulation of the arterial wall to changes in internal pressure. J Physiol. 1902;28:220-231.
63. McCarron JG, Osol G, Halpern W. Myogenic response are independent of the endothelium in rat pressurized posterior cerebral arteries. Blood Vessels. 1989;26:315-319.
64. Kuo L, Chilian WM, Davis MJ. Coronary arteriolar myogenic response is independent of endothelium. Circ Res. 1990;66:860-866.
65. Bevan JA, Laher I. Pressure and flow-dependent vascular tone. FASEB J. 1991;5:2267-2273.
66. Liu Y, Harder DR, Lombard JH. Myogenic activation of canine small renal arteries after nonchemical removal of the endothelium. Am J Physiol. 1994;267:H302-H307.
67. Pomposiello SI, Carroll MA, Falck JR, McGiff JC. Epoxyeicosatrienoic acid-mediated renal vasodilation to arachidonic acid is enhanced in SHR. Hypertension. 2001;37:887-893.
68. Pohl U, Lamontagne D, Bassenge E, Busse R. Attenuation of coronary autoregulation in the isolated rabbit heart by endothelium derived nitric oxide. Cardiovasc Res. 1994;28:414-419.
69. Juncos LA, Garvin J, Carretero OA, Ito S. Flow modulates myogenic responses in isolated microperfused rabbit afferent arterioles via endothelium-derived nitric oxide. J Clin Invest. 1995;95:2741-2748.
70. Lopez B, Moreno C, Salom MG, Roman RJ, Fenoy FJ. Role of guanylyl cyclase and cytochrome P-450 on renal response to nitric oxide. Am J Physiol Renal Physiol. 2001;281:F420-F427.
71. Alonso-Galicia M, Drummond HA, Reddy KK, Falck JR, Roman RJ. Inhibition of 20-HETE production contributes to the vascular responses to nitric oxide. Hypertension. 1997;29:320-325.
72. + channel activity and vascular tone in renal arterioles. Circ Res. 1998;83:1069-1079.
73. Sun CW, Falck JR, Okamoto H, Harder DR, Roman RJ. Role of cGMP versus 20-HETE in the vasodilator response to nitric oxide in rat cerebral arteries. Am J Physiol Heart Circ Physiol. 2000;279: H339-H350.
74. Alkayed NJ, Birks EK, Hudetz AG, Roman RJ, Henderson LXHDR. Inhibition of brain P-450 arachidonic acid epoxygenase decreases baseline cerebral blood flow. Am J Physiol Heart Circ Physiol. 1996; 271:H1541-H1546.
75. Alkayed NJ, Narayanan J, Gebremedhin D, Medhora M, Roman RJ, Harder DR. Molecular characterization of an arachidonic acid epoxygenase in rat brain astrocytes. Stroke. 1996;27:971-979.
76. Roman RJ, Maier KG, Sun CW, Harder DR, Alonso-Galicia M. Renal and cardiovascular actions of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids. Clin Exp Pharmacol Physiol. 2000;27: 855-865.
77. Zou AP, Ma Y-H, Sui Z-H, Ortiz de Montellano PR, Clark JE, Masters BS, Roman RJ. Effects of 17-octadecynoic acid, a suicide-substrate inhibitor of cytochrome P450 fatty acid ω-hydroxylase, on renal function in rats. J Pharmacol Exp Ther. 1994;268:474-481.
78. Bondy SC, Naderi S. Contribution of hepatic cytochrome P450 systems to the generation of reactive oxygen species. Biochem Pharmacol. 1994; 48:155-159.
79. Puntarulo S, Cederbaum AI. Production of reactive oxygen species by microsomes enriched in specific human cytochrome P450 enzymes. Free Radical Biol Med. 1998;24:1324-1330.
80. Davydov DR. Microsomal monooxygenase in apoptosis: another target for cytochrome c signaling? Trends Biochem Sci. 2001;26:155-160.
81. Popp R, Fleming I, Busse R. Pulsatile stretch elicits the release of the endothelium-derived hyperpolarizing factor from isolated coronary arteries: a modulator of arterial compliance. Circ Res. 1998;82: 696-703.
82. Hishikawa K, Oemar BS, Yang ZH, Luscher TF. Pulsatile stretch stimulates superoxide production and activates nuclear factor-κB in human coronary smooth muscle. Circ Res. 1997;81:797-803.
83. Hishikawa K, Luscher TF. Pulsatile stretch stimulates superoxide production in human aortic endothelial cells. Circulation. 1997;96: 3610-3616.
84. Wu D, Cederbaum AI. Removal of glutathione produces apoptosis and necrosis in HepG2 cells overexpressing CYP2E1. Alcohol Clin Exp Res. 2001;25:619-628.
85. Nieto N, Friedman SL, Greenwel P, Cederbaum A. CYP2E1-mediated oxidative stress induces collagen type I expression in rat hepatic stellate cells. Hepatology. 2001;30:987-996.
86. Yang B, Graham L, Dikalov S, Mason RP, Falck JR, Liao JK, Zeldin DC. Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol Pharmacol. 2001;60:310-320.
87. Gruenke LD, Konopka K, Cadieu M, Waskell L. The stoichiometry of the cytochrome P-450-catalyzed metabolism of methoxyflurane and benzphetamine in the presence and absence of cytochrome b5. J Biol Chem. 1995;270:24707-24718.
88. Li P-L, Chen C-L, Bortell R, Campbell WB. 11,12-Expoyeicosatrienoic acid stimulates endogenous mono-ADP-ribosylation in bovine coronary arterial smooth muscle. Circ Res. 1999;85:349-356.
89. + channels in coronary smooth muscle through a guanine nucleotide binding protein. Circ Res. 1997;80:877-884.
90. Uddin MR, Muthalif MM, Karzoun NA, Bentner IF, Malik KU. Cytochrome P-450 metabolites mediate norepinephrine-induced mitogenic signaling. Hypertension. 1998;31:242-247.
91. Fleming I, Fisslthaler B, Michaelis UR, Kiss L, Popp R, Busse R. The coronary endothelium-derived hyperpolarizing factor (EDHF) stimulates multiple signalling pathways and proliferation in vascular cells. Pflugers Arch. 2001;442:511-518.
92. Munzenmaier DH, Harder DR. Cerebral microvascular endothelial cell tube formation: role of astrocytic epoxyeicosatrienoic acid release. Am J Physiol Heart Circ Physiol. 2000;278:H1163-H1167.
93. Dhanasekaran N, Reddy EP. Signaling by dual specificity kinases. Oncogene. 1998;17:1447-1455.
94. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res. 1998;74:49-439.
95. Chen J-K, Falck JR, Reddy KM, Capdevila J, Harris RC. Epoxyeicosatrienoic acids and their sulfonimide derivatives stimulate tyrosine phosphorylation and induce mitogenesis in renal epithelial cells. J Biol Chem. 1998;273:29254-29261.
96. Chen JK, Capdevila J, Harris RC. Overexpression of C-terminal src kinase blocks 14, 15- epoxyeicosatrienoic acid-induced tyrosine phosphorylation and mitogenesis. J Biol Chem. 2000;275:13789-13792.
97. Chen J-K, Wang D-W, Falck JR, Capdevila J, Harris RC. Transfection of an active cytochrome P450 arachidonic acid epoxygenase indicates that 14,15-epoxyeicosatrienoic acid functions as an intracellular messenger in response to epidermal growth factor. J Biol Chem. 1999;274: 4764-4769.
98. Muthalif MM, Uddin MR, Fatima S, Parmentier J, Khandekar Z, Malik KU. Small GTP binding protein Ras contributes to norepinephrine-induced mitogenesis of vascular smooth muscle cells. Prostaglandins. 2001;65:33-43.
99. Karara A, Dishman E, Jacobson H, Falck JR, Capdevila JH. Arachidonic acid epoxygenase: stereochemical analysis of the endogenous epoxyeicosatrienoic acids of human kidney cortex. FEBS Lett. 1990;268: 227-230.
100. Wong PY, Lai PS, Falck JR. Mechanism and signal transduction of 14 (R), 15 (S)-epoxyeicosatrienoic acid (14,15-EET) binding in guinea pig monocytes. Prostaglandins Other Lipid Mediat. 2000;62:321-333.
101. Imig JD, Inscho EW, Deichamnn PC, Reddy KM, Falck JR. Afferent arteriolar vasodilation to the sulfonimide analog of 11,12-epoxyeicosatrienoic acid involves protein kinase A. Hypertension. 1999; 33:408-413.
102. Widstrom RL, Norris AW, Spector AA. Binding of cytochrome P450 monooxygenase and lipoxygenase pathway products by heart fatty acid-binding protein. Biochemistry. 2001;40:1070-1076.
103. Wolfrum C, Borrmann CM, Borchers T, Spener F. Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors α- and γ-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus. Proc Natl Acad Sci U S A. 2001;98:2323-2328.
104. Capdevila JH, Falck JR, Harris RC. Cytochrome P450 and arachidonic acid bioactivation: molecular and functional properties of the arachidonate monooxygenase. J Lipid Res. 2000;41:163-181.
105. Chen J, Capdevila JH, Zeldin DC, Rosenberg RL. Inhibition of cardiac L-type calcium channels by epoxyeicosatrienoic acids. Mol Pharmacol. 1999;55:288-295.
106. Ca, channels compensate for loss of NOS-dependent coronary artery relaxation in cardiomyopathy. Am J Physiol Heart Circ Physiol. 2000;279:H2598-H2603.
107. Malmsjö M, Bergdahl A, Zhao X-H, Sun X-Y, Hedner T, Edvinsson L, Erlinge D. Enhanced acetylcholine and PY2-receptor stimulated vascular EDHF-dilatation in congestive heart failure. Cardiovasc Res. 1999;43:200-209.
108. Taddei S, Ghiadoni L, Virdis A, Buralli S, Aalvetti A. Vasodilation to bradykinin is mediated by an ouabain-sensitive pathway as a compensatory mechanism for impaired nitric oxide availability in essential hypertensive patients. Circulation. 1999;100:1400-1405.
109. Yu Z, Huse LM, Adler P, Graham L, Ma J, Zeldin DC, Kroetz DL. Increased CYP2J expression and epoxyeicosatrienoic acid formation in spontaneously hypertensive rat kidney. Mol Pharmacol. 2000;57: 1011-1020.
110. Frisbee JC, Falck JR, Lombard JH. Contribution of cytochrome P-450 omega-hydroxylase to altered arteriolar reactivity with high-salt diet and hypertension. Am J Physiol Heart Circ Physiol. 2000;278: H1517-H1526.
111. Kroetz DL, Huse LM, Thuresson A, Grillo MP. Developmentally regulated expression of the CYP4A genes in the spontaneously hypertensive rat kidney. Mol Pharmacol. 1997;52:362-372.
112. Omata K, Abraham NG, Escalante B, Schwartzman ML. Age-related changes in renal cytochrome P-450 arachidonic acid metabolism in spontaneously hypertensive rats. Am J Physiol. 1992;262:F8-F16.
113. Holla VR, Makita K, Zaphiropoulos PG, Capdevila JH. The kidney cytochrome P-450 2C23 arachidonic acid epoxygenase is upregulated during dietary salt loading. J Clin Invest. 1999;104:751-760.
114. Pfister SL, Falck JR, Campbell WB. Enhanced synthesis of epoxyeicosatrienoic acids by cholesterol-fed rabbit aorta. Am J Physiol. 1991;261: H843-H852.
115. Fang X, Kaduce TL, Weintraub NL, VanRollins M, Spector AA. Functional implications of a newly characterized pathway of 11,12-epoxyeicosatrienoic acid metabolism in arterial smooth muscle. Circ Res. 1996;79:784-793.
116. Fang X, Kaduce TL, Weintraub NL, Spector AA. Cytochrome P450 metabolites of arachidonic acid: rapid incorporation and hydration of 14,15-epoxyeicosatrienoic acid in arterial smooth muscle cells. Prostaglandins Leukot Essent Fatty Acids. 1997;57:367-371.
117. VanRollins M, Kaduce TL, Knapp HR, Spector AA. 14,15-Epoxyeicosatrienoic acid metabolism in endothelial cells. J Lipid Res. 1993;34:1931-1942.
118. Weintraub NL, Fang X, Kaduce TL, VanRollins M, Chatterjee P, Spector AA. Epoxide hydrolases regulate epoxyeicosatrienoic acid incorporation into coronary endothelial phospholipids. Am J Physiol. 1999;277:H2098-H2108.
119. Sinal CJ, Miyata M, Tonkin M, Nagata K, Bend JR, Gonzalez FJ. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem. 2000;275:40504-40510.
120. Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, Parker C, Graham L, Engler MM, Hammock BD, Zeldin DC, Kroetz DL. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res. 2000;87:992-998.
121. Ito O, Alonso-Galicia M, Hopp KA, Roman RJ. Localization of cytochrome P-450 4A isoforms along the rat nephron. Am J Physiol. 1998; 274:F395-F404.
122. Roman RJ, Ma YH, Frohlich B, Markham B. Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats. Hypertension. 1993;21:985-988.
123. Chu ZM, Croft KD, Kingsbury DA, Falck JR, Reddy KM, Beilin LJ. Cytochrome P450 metabolites of arachidonic acid may be important mediators in angiotensin II-induced vasoconstriction in the rat mesentery in vivo. Clin Sci. 2000;98:277-282.
124. Su P, Kaushal KM, Kroetz DL. Inhibition of renal arachidonic acid omega-hydroxylase activity with ABT reduces blood pressure in the SHR. Am J Physiol. 1998;275:R426-R438.
125. Gebremedhin D, Ma YH, Imig JD, Harder DR, Roman RJ. Role of cytochrome P-450 in elevating renal vascular tone in spontaneously hypertensive rats. J Vasc Res. 1993;30:53-60.
126. MesserLetienne I, Bernard N, Benzoni D, Sassard J. Cytochrome P-450-dependent arachidonate metabolites and renal functions in the Lyon hypertensive rat. Clin Exp Pharmacol Physiol. 1998;25:559-563.
127. Moreno C, Maier KG, Hoagland KM, Yu M, Roman RJ. Abnormal pressure-natriuresis in hypertension: role of cytochrome P450 metabolites of arachidonic acid. Am J Hypertens. 2001;14:90S-97S.
128. Iwai N, Inagami T. Isolation of preferentially expressed genes in the kidneys of hypertensive rats. Hypertension. 1991;17:161-169.
129. Omata K, Abraham NG, Schwartzman ML. Renal cytochrome P-450-arachidonic acid metabolism: localization and hormonal regulation in SHR. Am J Physiol. 1992;262:F591-F599.
130. Omata K, Tsutsumi E, Sheu HL, Utsumi Y, Abe K. Effect of aging on renal cytochrome P450-dependent arachidonic acid metabolism in Dahl rats. J Lipid Mediat. 1993;6:369-373.
131. Wang MH, Zhang F, Marji J, Zand BA, Nasjletti A, Laniado-Schwartzman M. CYP4A1 antisense oligonucleotide reduces mesenteric vascular reactivity and blood pressure in SHR. Am J Physiol Regul Integr Comp Physiol. 2001;280:R255-R261.
132. Holla VR, Adas F, Imig JD, Zhao X, Price E Jr, Olsen N, Kovacs WJ, Magnuson MA, Keeney DS, Breyer MD, Falck JR, Waterman MR, Capdevila JH. Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension. Proc Natl Acad Sci U S A. 2001; 98:5211-5216.
133. Nelson DR. Cytochrome P450 and the individuality of the species. Arch Biochem Biophys. 1999;369:1-10.
134. Garcia-Martin E, Martinez C, Ladero JM, Gamito FJG, Agúndez JAG. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population. Eur J Clin Pharmacol. 2001;57:47-49.
135. Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP, Shimada T. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics. 1997; 7:103-113.
136. Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, Schwarz UI. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol. 2001;60:382-387.
137. Hashimoto Y, Otsuki Y, Odani A, Takano M, Hattori H, Furusho K, Lui K. Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Biol Pharm Bull. 1996;19: 1103-1105.
138. Yasar U, Tybring G, Hidestrand M, Oscarson M, Ingelman-Sundberg M, Dahl ML, Eliasson E. Role of cyp2c9 polymorphism in losartan oxidation. Drug Metab Dispos. 2001;29:1051-1056.
139. Transon C, Leemann T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol. 1996;50:209-215.